Insight Molecular Diagnostics (IMDX) Depreciation and Depletion (2015 - 2023)

Insight Molecular Diagnostics has disclosed Depreciation and Depletion across 9 years of filings, most recently posting $404000.0 for Q3 2023.

• Depreciation and Depletion for Q3 2023 came in at $404000.0, up 3.32% year-over-year; the trailing twelve-month figure through Sep 2023 was $1.8 million (up 32.55% YoY), and the FY2022 annual result was $1.5 million, up 81.04% from the prior year.
• Depreciation and Depletion came in at $404000.0 for Q3 2023 at Insight Molecular Diagnostics, down from $435000.0 in the prior quarter.
• In the past five years, Depreciation and Depletion ranged from a high of $466000.0 in Q4 2022 to a low of -$216000.0 in Q4 2020.
• The 5-year median for Depreciation and Depletion is $206000.0 (2021), against an average of $209736.8.
• Across the five-year window, Depreciation and Depletion tumbled 427.27% in 2020 and soared 269.57% in 2021, its largest moves.
• Insight Molecular Diagnostics' Depreciation and Depletion stood at $66000.0 in 2019, then sank by 427.27% to -$216000.0 in 2020, then soared by 221.3% to $262000.0 in 2021, then surged by 77.86% to $466000.0 in 2022, then dropped by 13.3% to $404000.0 in 2023.
• The last three Depreciation and Depletion figures came in at $404000.0 (Q3 2023), $435000.0 (Q2 2023), and $450000.0 (Q1 2023), per Business Quant data.